Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
OBJECTIVE
To evaluate and describe the parameters and characteristics of different drug regimens in children infected with human immunodeficiency virus (HIV).


METHODS
Randomized, open-label, multicenter study.


METHODS
Pediatric HIV research clinics in the United States and Puerto Rico.


METHODS
Twenty-one HIV-infected children, aged 3-14 years, who were clinically stable and treated with the same antiretroviral therapy for 16 weeks or longer.


METHODS
In step 1, children were randomized to receive one of three treatment regimens: zidovudine plus lamivudine, ritonavir plus zidovudine and lamivudine, or ritonavir plus stavudine. Patients originally assigned to the zidovudine plus lamivudine group in step 1 were eligible to progress to step 2 if their HIV RNA values at week 12, 24, or 36 were 10,000 copies/ml or greater but 100,000 copies/ml or less. In step 2 they received a regimen of ritonavir plus stavudine and nevirapine.


RESULTS
Seven children were randomized to each of the three treatment regimens. Concentrations of the agents were quantitated at steady state after observed doses, and the pharmacokinetic parameters were determined. Nevirapine concentrations were not determined. One child was excluded from analysis because pharmacokinetic parameters could not be estimated. Ritonavir oral clearance was slower in the pooled cohort of children who received stavudine compared with zidovudine and lamivudine. Stavudine oral clearance was marginally faster when combined with ritonavir and nevirapine compared with only ritonavir.


CONCLUSIONS
Therapy for HIV is complex, and pharmacodynamic data indicate that relationships exist between systemic concentrations of antiretroviral drugs and virologic response. Careful drug interaction studies have not been conducted for all treatment regimens, and it will not be surprising if unexpected interactions are found. Pharmacokinetic studies to address these considerations should be viewed as a fundamental component of antiretroviral drug development, as they represent a tool to improve pharmacotherapy for HIV-infected children.
Fletcher
Courtney V
CV
Pediatric AIDS Clinical Trials Group and the Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA. courtney.fletcher@uchsc.edu
Yogev
Ram
R
Nachman
Sharon A
SA
Wiznia
Andrew
A
Pelton
Stephen
S
McIntosh
Kenneth
K
Stanley
Kenneth
K
D000293:Adolescent; D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D002648:Child; D002675:Child, Preschool; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006207:Half-Life; D006801:Humans; D019259:Lamivudine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D008657:Metabolic Clearance Rate; D019438:Ritonavir / Q000493:pharmacokinetics* / Q000627:therapeutic use; D018119:Stavudine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015215:Zidovudine / Q000493:pharmacokinetics* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D018119:Stavudine; D019438:Ritonavir